Melbourne 8 Feb 2016: Cell collection via apheresis is the starting point for manufacture of many cellular therapies, including most immuno-therapies. The high patient-to-patient variability, coupled with the specialised skills needed for these collections mean manufacturers have to deal with significant variation in incoming cellular material. Manufacturers are only now coming to grips with the implications of this variation, let alone how to manage and control it. Cell Therapies Pty Ltd CEO Tim Oldham discussed the importance of understanding apheresis variability and approaches to managing and controlling it at the recent Cell & Gene Therapy Leaders Forum in Washington DC (see the presentation Managing apheresis as source of cellular therapy starting material) and Alexey Bersenev has followed up with a useful blog at Stem Cell Assays (http://stemcellassays.com/2016/01/standardization-of-apheresis-collections-for-cell-product-manufacturing/#comments). Dr Oldham argued that collating collection data across many centres and collections to enable apheresis variability to be characterized and understood, and to benchmark individual site, operator and collection performance would be an invaluable tool to aid manufacturing process development.
- The fast path to first-in-human cell therapy trials September 6, 2021
- Protecting your cell therapy trial by building resilience in your supply chain September 7, 2021
- New cancer treatment approved in Australia December 19, 2018
- Cell Therapies Pty Ltd facility accredited by the Ministry of Health, Labour and Welfare in Japan June 21, 2021
- ISO certifications accredited to Cell Therapies Pty Ltd management systems April 30, 2021